ADO antibody

Catalog No. ABIN5647727

Product Details anti-ADO Antibody

Target: ADO (2-Aminoethanethiol (Cysteamine) Dioxygenase (ADO))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This ADO antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS)

Purification: Antigen affinity purified

Immunogen: Amino acids E49-E261 from the human protein were used as the immunogen for the ADO antibody.

Isotype: IgG

Application Details

Application Notes: Western blot: 0.5-1 μg/mL,FACS: 1-3 μg/10^6 cells

Restrictions: For Research Use only

Handling

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: -20 °C

Storage Comment: After reconstitution, the ADO antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Target Details for ADO

Target: ADO (2-Aminoethanethiol (Cysteamine) Dioxygenase (ADO))

Alternative Name: ADO / 2-Aminoethanethiol dioxygenase (ADO Products)

Synonyms: C10orf22 antibody, Gm237 antibody, RGD1308233 antibody, wu:fc32g01 antibody, wu:fc52c12 antibody, zgc:101580 antibody, 2-aminoethanethiol dioxygenase antibody, 2-aminoethanethiol (cysteamine) dioxygenase antibody, 2-aminoethanethiol (cysteamine) dioxygenase a antibody, ADO antibody, Ado antibody, LOC100351598 antibody, adoa antibody

Background: Human thiol dioxygenases include cysteine dioxygenase (CDO) and cysteamine (2-aminoethanethiol) dioxygenase (ADO). CDO adds 2 oxygen atoms to free cysteine, whereas ADO adds 2 oxygen atoms to free cysteamine to form hypotaurine. It is demonstrated that mouse Ado has strong and specific dioxygenase activity in vitro towards cysteamine but not cysteine. Recombinant Ado was shown to bind iron. Overexpression of Ado in HepG2/C3A cells increased the production of hypotaurine from cysteamine. Similar results were found with human ADO. When endogenous expression of ADO was reduced by RNA-mediated interference, hypotaurine production decreased. It is also noted that the demonstration of high levels of ADO in brain challenges the previous assumption that most of the taurine in the brain is a consequence of CDO activity.

UniProt: Q96SZ5